noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Pharmaceuticals and Biotechnology

MHRA - Medicines and Healthcare[...]

Antidepressants – updated safety communications
MHRA - Medicines and Healthcare[...]

MHRA introduces new safeguards to strengthen antidepressant safety[...]
ANSM - French Agency for the[...]

Matériel ancillaire (genou) – Unity ASC Poignée Modulaire – Corin Ltd

Economy, Business and Finance

Max Biopharma Inc

06/14/2025 | Press release | Archived content

Oxy210 Inhibits Atherosclerosis in Preclinical Models

MAX BioPharma reports on the Inhibition of Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells by its Oxysterol Drug Candidate, Oxy210

Paper available from https://pubmed.ncbi.nlm.nih.gov/39404395/

Max Biopharma Inc published this content on June 14, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 15, 2026 at 07:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format